AbbVie Signs an Exclusive Agreement with Scripps Research to Develop New Therapies Targeting Multiple Therapeutic Areas

 AbbVie Signs an Exclusive Agreement with Scripps Research to Develop New Therapies Targeting Multiple Therapeutic Areas

AbbVie, Signs, Exclusive, Agreement, Scripps Research, Develop, New Therapies, Targeting, Multiple Therapeutic Areas

Shots:

  • Scripps Research to receive up front, development & commercialization milestones, option exercise fee and royalties on sales of new therapies and will conduct pre-clinical R&D activities and P-I studies (in some cases) while AbbVie get an exclusive option to further develop and commercialize therapies for cancer, immunology, neurology and fibrosis
  • The collaboration marks the expansion of companies’ partnership signed in 2018, to develop T-cell therapies targeting solid tumors
  • Additionally, Scripps Research will offer preclinical programs to AbbVie of mutual interest/yr. for consideration to be included in the collaboration. The companies will also work to advance CD3 bispecific against oncology targets selected by AbbVie

Click here to­ read full press release/ article | Ref: AbbVie | Image: Chicago Sun times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post